Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients

: Sharma, Ashish; Hohlfeld, Jens; Cornelissen, Piet; Noord, Jan van; Derom, Eric; Towse, Lesley; Peterkin, Vicky; Disse, Bernd

European Respiratory Journal 42 (2013), Supplement 57, pp.981s
ISSN: 0903-1936
ISSN: 1399-3003
European Respiratory Society (Annual Congress) <23, 2013, Barcelona>
Journal Article, Conference Paper
Fraunhofer ITEM ()

Background/Objective: Primary objective of this study was to characterize the pharmacokinetics of tiotropium Respimat® 5g (R5) in comparison with tiotropium HandiHaler® 18g (HH18). Secondary objective was to assess the dose-dependency of bronchodilator effi cacy (FEV1, FVC) by including 2 lower tiotropium Respimat® doses (1.25g and 2.5g) and placebo.
Methods: Multicentre, placebo-controlled, randomised, double-blind (within Respimat® device), 5-way crossover trial with 4-week treatment periods in 154 patients. Primary endpoints were peak plasma concentration (Cmax,ss) and area under the plasma concentration-time profile (AUC0-6h,ss), with first sample 2 min following inhalation.
Results: Tiotropium was rapidly absorbed, showing no difference between devices, with a median tmax,ss of 5-7 min post-dosing. Pharmacokinetics of tiotropium Respimat® treatments (R5, R2.5 and R1.25) was dose proportional. The bioavailability of R5 was lower than HH18. The gMean ratio of Test/Reference for R5/HH18 was 81% (90% CI 73% to 89%) for Cmax,ss and 76% (90% CI 70% to 82%) for AUC0-6h,ss, indicating that bioequivalence was not established pointing to lower systemic exposure with R5. Dose-ordering for bronchodilation was evident for the Respimat® doses, with R5 showing similar efficacy to HH18. Treatments were safe and well tolerated with no apparent differences between devices.
Conclusions: The bioavailability of R5 was lower than HH18. In view of lower systemic exposure and similar bronchodilator efficacy, these results support the currently marketed R5 dose for the once-daily maintenance therapy of COPD patients.